TELA NASDAQ
TELA Bio, Inc.
1W: -9.5%
1M: +51.5%
3M: +45.0%
YTD: +0.0%
1Y: -24.0%
3Y: -85.5%
5Y: -91.2%
$1.14
-0.11 (-8.80%)
Weekly Expected Move ±13.5%
$1
$1
$1
$1
$1
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (37)
TELA Bio, Inc. (NASDAQ:TELA) Stock Has Average Price Target of $2.17
Insider Buying: TELA Bio (NASDAQ:TELA) Director Acquires $30,500.00 in Stock
TELA Bio (TELA) Q2 2026 Earnings Call Transcript
TELA Bio, Inc. (TELA) Reports Q2 Loss, Lags Revenue Estimates
Puma Biotech (PBYI) Q2 Earnings and Revenues Top Estimates
TELA Bio names Heather Getz as CEO and Director
12 Health Care Stocks Moving In Tuesday's After-Market Session
After Fifty Years of Implants, a Newly Public Biotech Is Trying to Rebuild the Breast Instead
TELA Bio, Inc. (TELA) Reports Q1 Loss, Beats Revenue Estimates
12 Health Care Stocks Moving In Tuesday's After-Market Session
Earnings Scheduled For May 12, 2026
AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Beats Revenue Estimates
BridgeBio Pharma (BBIO) Reports Q1 Loss, Tops Revenue Estimates
12 Health Care Stocks Moving In Friday's After-Market Session
TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 Revenues
TELA Bio to Announce First Quarter 2026 Financial Results
TELA Bio, Inc. (NASDAQ:TELA) Short Interest Update
TELA Bio, Inc. (NASDAQ:TELA) Receives Consensus Rating of “Hold” from Brokerages
TELA Bio Analysts Cut Their Forecasts After Q4 Results
Amazon To Rally Around 49%? Here Are 10 Top Analyst Forecasts For Wednesday
Tela Bio targets at least 8% revenue growth in 2026 while advancing commercial transformation
TELA Bio (TELA) Q4 2025 Earnings Call Transcript
TELA Bio, Inc. (TELA) Reports Q4 Loss, Lags Revenue Estimates
TELA Bio GAAP EPS of -$0.17 beats by $0.01, revenue of $20.9M misses by $0.14M
TELA Bio Reports Fourth Quarter and Full Year 2025 Financial Results
TELA Bio Reports Fourth Quarter and Full Year 2025 Financial Results
Earnings Scheduled For March 24, 2026
Quant snapshot: AAR, Noah Holdings lead strong buys as Blaize, Fractyl Health lag
Assembly Biosciences (ASMB) Q4 Earnings and Revenues Top Estimates
TELA Bio, Inc. (NASDAQ:TELA) Given Average Rating of “Hold” by Brokerages
TELA Bio, Inc. (NASDAQ:TELA) Sees Large Growth in Short Interest
Astrana Health, Inc. (ASTH) Q4 Earnings and Revenues Surpass Estimates
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TELA Bio, Inc. (NASDAQ:TELA) Receives Consensus Recommendation of “Hold” from Analysts
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TELA Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference